• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by GlaxoSmithKline PLC (Amendment)

    5/25/21 4:24:54 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GSK alert in real time by email
    SC 13D/A 1 inno-sc13da_052521.htm AMENDED SCHEDULE 13D

     

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13D

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a)

    (Amendment No. 9)*

     

     

     

    INNOVIVA, INC.
    (Name of Issuer)

     

    Common Stock
    (Title of Class of Securities)

     

    45781M101
    (CUSIP Number)

     

    Victoria A. Whyte
    GlaxoSmithKline plc
    980 Great West Road
    Brentford, Middlesex TW8 9GS
    England
    Telephone: +44 (0)208 047 5000
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    May 20, 2021
    (Date of Event Which Requires Filing of This Statement)

     

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box.  ☐

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

      * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 45781M101 Page 2

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. Identification Nos. of above persons (entities only).

     

    GlaxoSmithKline plc

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a)☐ (b) ☐

     

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

     

    WC

     

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

     

    6

    CITIZENSHIP OR PLACE OR ORGANIZATION

     

    England and Wales

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7

    SOLE VOTING POWER

     

    0

     

    8

    SHARED VOTING POWER

     

    0

     

    9

    SOLE DISPOSITIVE POWER

     

    0

     

    10

    SHARED DISPOSITIVE POWER

     

    0

     

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

     

    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0%

     

    14

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO

     

           

     

     

     

     

    CUSIP No. 45781M101 Page 3

     

    This Amendment No. 9 to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on December 9, 2010 (as amended by Amendment No. 1 filed on April 2, 2012, Amendment No. 2 filed on May 16, 2012, Amendment No. 3 filed on August 1, 2013, Amendment No. 4 filed on November 4, 2014, Amendment No. 5 filed on August 25, 2016, Amendment No. 6 filed on April 13, 2017, Amendment No. 7 filed on April 10, 2018 and Amendment No. 8 filed on February 12, 2021, the “Schedule 13D” and as amended by this Amendment No. 9, the “Statement”) with respect to the shares of common stock, par value $0.01 per share (the “Common Stock”) of Innoviva, Inc., a Delaware corporation (the “Issuer”). The Issuer’s principle executive offices are located at 2000 Sierra Point Parkway, Suite 500, Brisbane, CA 94005.

     

    GlaxoSmithKline plc is filing this amendment to amend and restate Item 4 in its entirety.

     

    Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Schedule 13D.

     

     

    Item 2. Identity and Background.

     

    The response set forth in Item 2 of the Schedule 13D is hereby amended by deleting Schedule 1 in its entirety and replacing it with Schedule 1 attached.

     

     

    Item 4. Purpose of Transaction.

     

    Item 4 is hereby superseded and replaced to read in full as follows:

     

    Pursuant to a share repurchase agreement by and between Glaxo Group Limited ("GGL"), an indirect wholly owned subsidiary of the Reporting Person, and Innoviva, Inc. (the "Issuer") dated as of May 20, 2021 (the “Repurchase Agreement”), the Reporting Person sold 32,005,260 shares of its common stock, par value $0.01 per share, to the Issuer, representing all of the shares of common stock owned by the Reporting Person or its affiliates. The purchase price under the Repurchase Agreement was $12.25 per share, resulting in a total consideration of $392,064,435. The transaction closed on May 25, 2021.

     

     

     

     

    CUSIP No. 45781M101 Page 4

     

    Item 5.   Interest in Securities of the Issuer.

     

    The disclosure previously contained in Item 5 is hereby superseded and replaced to read as follows:

     

      (a), (b) As a result of the consummation of the Repurchase Agreement, the Reporting Person no longer has beneficial ownership of any shares of the Issuer’s Common Stock.

     

      (c) Except as set forth in Item 4 of this Schedule 13D, neither the Reporting Person nor, to the best knowledge of the Reporting Person, without independent verification, any person named in Item 2 hereof, has effected any transaction in the Common Shares during the past 60 days.

     

      (d) No person other than the Reporting Person and GGL has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities.

     

      (e) The Reporting Person ceased to be a beneficial owner of 5% or more of the Issuer’s Common Stock on the Effective Time. Therefore, this is the final amendment to the Statement and an exit filing for the Reporting Person.

    Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    The information contained in Item 4 is incorporated herein by reference.

     

    Item 7.  Material to Be Filed as Exhibits.

     

    Descriptions of documents set forth on this Schedule are qualified in their entirety by reference to the exhibits listed in this Item 7.

     

    Exhibit   Name
    7   Share Repurchase Agreement by and between the Issuer and Glaxo Group Limited dated as of May 20, 2021, a copy of which is incorporated herein by reference from Exhibit 10.1 to the amended current report on Form 8-K filed by the Issuer on May 20, 2021.

     

     

     

     

    CUSIP No. 45781M101 Page 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: May 25, 2021

     

      GLAXOSMITHKLINE PLC
         
      By: /s/ Victoria A. Whyte
      Victoria A. Whyte
    Authorized Signatory

     

     

     

     

    CUSIP No. 45781M101 Page 6

     

    Schedule 1

     

    Name 

    Business Address 

    Principal Occupation or Employment 

    Citizenship 

    Board of Directors      
    Emma Walmsley 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Executive Director and Chief Executive Officer British
    Charles Bancroft 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS

    Company Director

     

     

     

    US
    Manvinder Singh Banga 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS

    Company Director

     

     

     

    British & Indian

     

     

     

    Dr. Hal Barron

    269 E. Grand Avenue,

    South San Francisco,

    CA 94080

     

    Chief Scientific Officer & President, R&D US
    Dr Anne Beal 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Company Director US
    Dr. Vivienne Cox 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Company Director British
    Lynn Elsenhans 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Company Director US
    Dr. Jesse Goodman 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Company Director US
    Dr Laurie Glimcher 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Company Director US

     

     

     

     

    CUSIP No. 45781M101 Page 7

     

    Iain MacKay 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Executive Director & Chief Financial Officer British

    Urs Rohner

     

     

     

    980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Company Director Swiss
    Sir Jonathan Symonds 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Chairman and Company Director British

     

    Corporate Executive Team      
    Emma Walmsley 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Executive Director and Chief Executive Officer British
    Dr. Hal Barron

    269 E. Grand Avenue,

    South San Francisco,

    CA 94080

     

    Chief Scientific Officer & President, R&D

     

     

     

    US
    Roger Connor 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    President, Global Vaccines Irish
    Diana Conrad 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Senior Vice President, Human Resoures Canadian
    James Ford 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Senior Vice President & General Counsel British & US
    Nick Hirons 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Senior Vice President, Global Ethics and Compliance British & US
    Sally Jackson 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Senior Vice President, Global Communications and CEO Office British

     

     

     

     

    CUSIP No. 45781M101 Page 8

     

    Iain MacKay 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Executive Director & Chief Financial Officer British
    Brian McNamara 184 Liberty Corner Road
    Warren
    NJ, 07059
    Chief Executive Officer, GSK Consumer Healthcare US

    Luke Miels

     

     

    980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    President, Global Pharmaceuticals Australian
    David Redfern 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Chief Strategy Officer British
    Regis Simard 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    President Pharmaceutical Supply Chain French & British
    Karenann Terrell 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Chief Digital and Technology Officer Canadian
    Philip Thomson 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    President, Global Affairs British
    Deborah Waterhouse 980 Great West Road
    Brentford
    Middlesex, England
    TW8 9GS
    Chief Executive Officer of ViiV Healthcare British

     

     

     

    Get the next $GSK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GSK

    DatePrice TargetRatingAnalyst
    4/15/2025$35.25Neutral
    Exane BNP Paribas
    2/12/2025Equal-Weight
    Morgan Stanley
    11/15/2024Buy → Hold
    Deutsche Bank
    11/12/2024$53.00 → $39.50Buy → Hold
    Jefferies
    10/31/2024Buy → Neutral
    Guggenheim
    7/8/2024Buy → Neutral
    UBS
    5/30/2024$47.00Neutral
    Goldman
    3/4/2024Neutral → Buy
    Guggenheim
    More analyst ratings

    $GSK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

      Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.

      5/9/25 9:00:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

      --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD). Alector and GSK are co-developing AL101, an investigational hum

      4/17/25 8:00:00 AM ET
      $ALEC
      $GSK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices

      Over 13 million adults aged 50-59 at increased risk in the US can potentially benefit from RSV immunization1 RSV causes an estimated 42,000 hospitalizations* each year in adults aged 50-64 years old in the US2 GSK plc (LSE/NYSE:GSK) is pleased that the Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of RSV vaccines including GSK's AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 50-59 who are at increased risk for severe RSV disease. This includes people with conditions like COPD, asthma, diabetes, heart disease and those in residential care3. This expands on ACIP's previous vote in June 2024 to recommend RSV vaccines fo

      4/16/25 5:36:00 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on GlaxoSmithKline with a new price target

      Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25

      4/15/25 12:40:46 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on GlaxoSmithKline

      Morgan Stanley initiated coverage of GlaxoSmithKline with a rating of Equal-Weight

      2/12/25 7:05:11 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlaxoSmithKline downgraded by Deutsche Bank

      Deutsche Bank downgraded GlaxoSmithKline from Buy to Hold

      11/15/24 7:46:43 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: GLAXOSMITHKLINE PLC converted options into 700,772 units of Common Stock and bought $4,950,000 worth of Common Stock (275,000 units at $18.00)

      4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

      7/6/21 4:38:14 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by GLAXOSMITHKLINE PLC

      3 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

      7/6/21 4:22:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: GLAXOSMITHKLINE PLC converted options into 30,253,189 units of Common Stock

      4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

      6/23/21 6:14:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    Financials

    Live finance-specific insights

    See more
    • Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

      Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include

      8/6/24 4:05:00 PM ET
      $GSK
      $MYGN
      $PSNL
      $QGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Medical Specialities
    • GSK and CureVac to Restructure Collaboration into New Licensing Agreement

      GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replacedLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA

      7/3/24 2:40:00 AM ET
      $CVAC
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Reports Third Quarter Fiscal 2024 Financial Results

      SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023. Key Results Reported total revenue of $44.7 million in the third quarter of fiscal 2024, compared to $66.9 million in the third quarter of fiscal 2023, a decrease of approximately 33% due to lower research revenue after the conclusion of the GSK collaboration exclusivity term in July 2023 and lower PGS kit volumes.Announced a non-exclusive data license with GSK plc (NYSE:GSK) for novel drug target discovery and other research. U

      2/7/24 4:01:00 PM ET
      $GSK
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    Leadership Updates

    Live Leadership Updates

    See more
    • GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

      Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.

      5/9/25 9:00:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

      TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

      11/18/24 7:30:00 AM ET
      $GSK
      $MDCX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    SEC Filings

    See more
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/9/25 10:05:59 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/8/25 1:49:29 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/8/25 11:26:51 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GSK plc

      SC 13G/A - GSK plc (0001131399) (Subject)

      11/12/24 4:32:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by GSK plc (Amendment)

      SC 13G/A - GSK plc (0001131399) (Subject)

      2/13/24 1:37:25 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by GSK plc (Amendment)

      SC 13G/A - GSK PLC (0001131399) (Subject)

      2/14/23 1:54:01 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care